<DOC>
	<DOCNO>NCT00586469</DOCNO>
	<brief_summary>Vaccination currently effective mean control influenza prevent complication mortality person risk . Once year , meet World Health Organization ( WHO ) expert take place , lead recommendation influenza A B strain use production vaccine come influenza season . For strain change previous year , vaccine formulate old mono bulk previous year . Bulks old 12 month may blend make trivalent inactivate vaccine ( TIV ) current Canadian US license . This study conduct evaluate safety immunogenicity Fluviral vaccine make age bulk material compare new bulk material . This protocol post updated order comply FDA Amendment Act , Sept 2007 .</brief_summary>
	<brief_title>A Randomized Study Compare Safety Immunogenicity Fluviral® Made With New Versus Aged Bulk</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<criteria>Subjects investigator believe comply requirement protocol enrol study . Male female adult , 18 60 year . Written inform consent obtain subject . If subject female , must nonchildbearing potential childbearing potential , must practice adequate contraception 30 day prior vaccination , negative pregnancy test continue precaution duration study . Acute disease time enrollment . Any confirm suspected immunosuppressive condition Presence blood dyscrasia , include hemaglobinopathies myelo lymphoproliferative disorder . Chronic administration immunosuppressant immunemodifying drug within six month prior first vaccine dose . A history demyelinate disease include GuillainBarré syndrome . Presence active neurological disorder . Any significant disorder coagulation increase risk intramuscular injection treatment coumadin derivative heparin . Receipt influenza vaccine within 6 month prior study enrollment . Administration vaccine within 30 day prior study enrollment study period . Use investigational nonregistered product ( drug vaccine ) study vaccine ( ) within 30 day precede vaccination plan use study period . Administration immunoglobulins and/or blood product within three month precede administration study vaccine plan study . Any known suspected allergy constituent Fluviral and/or history anaphylactic type reaction consumption egg , and/or reaction product contain mercury . A history severe adverse reaction previous influenza vaccination . Lactating/nursing female . Any condition , opinion investigator , prevents subject participation study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Influenza</keyword>
</DOC>